Physician profile
Mitchell Schuster
NPI 1245299874
$7,229.59
in general payments reported to CMS, 2019-2025
34 companies · $591 in 2025
The $591 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $120 · 2021: $2,726 · 2022: $742 · 2023: $732 · 2024: $2,125 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612 · Travel and Lodging: $780 · Gift: $55.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.06 |
| Travel and Lodging | $779.65 |
| Gift | $55.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $2,400.00 | 2021 | |
| Intuitive Surgical, INC. | $1,739.33 | 2019-2024 | |
| Pfizer INC. | $419.78 | 2019-2024 | |
| Astellas Pharma US INC | $368.84 | 2021-2025 | Veozah, Myrbetriq |
| Coloplast Corp | $259.55 | 2022-2023 | Altis |
| Sage Therapeutics, LLC | $185.55 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $172.39 | 2022-2025 | |
| Shield Therapeutics INC | $171.46 | 2024-2025 | |
| Channel Medsystems, INC. | $160.87 | 2022-2023 | |
| Exeltis, USA INC. | $153.11 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $150.71 | 2019-2021 | |
| Medtronic, INC. | $130.96 | 2022-2024 | Interstim |
| Abbvie INC. | $130.24 | 2021-2024 | Liletta |
| Axonics, INC. | $100.02 | 2023-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $82.13 | 2019-2025 | Solyx Sis System, Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $80.15 | 2023-2025 | Gemtesa, Myfembree |
| Aspira Women'S Health INC | $60.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.25 | 2023-2025 | |
| Laborie Medical Technologies Corp. | $48.04 | 2022-2024 | Eclipse |
| Supernus Pharmaceuticals, INC. | $45.41 | 2025 | Qelbree |
| Caldera Medical, INC | $40.93 | 2023 | Desara |
| Myovant Sciences INC. | $38.89 | 2021-2022 | |
| Exact Sciences Corporation | $37.96 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $29.49 | 2021 | |
| Millicent US INC | $21.41 | 2025 | Intrarosa |
| Hologic Sales and Service, LLC | $20.88 | 2022 | |
| Roche Diagnostics Corporation | $18.30 | 2021 | |
| Monaghan Medical Corporation | $18.29 | 2023 | Aeroeclipse |
| Conmed Corporation | $18.00 | 2024 | Airseal |
| Heron Therapeutics, INC. | $17.02 | 2024 | Zynrelef |
| Smith+Nephew, INC. | $15.73 | 2021 | |
| Merck Sharp & Dohme LLC | $15.15 | 2023 | Gardasil 9 |
| Therapeuticsmd, INC. | $12.70 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Schuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.